A long-term open assessment of sublingual buprenorphine in patients suffering from chronic pain

Adriaensen, H.; Mattelaere, B.; Vanmeenen, H

doi:10.1016/0304-3959(81)90251-7

Cited by 10 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data on the use of BUP in cancer patients are limited and few studies have assessed dose issues, although in some early trials of sublingual BUP doses up to 3.2 mg/day have been reported, with most patients taking between 0.8 and 1.6 mg [1]. In other studies, the most frequent reason for changing BUP therapy was the problem in having to use large numbers of BUP tablets sublingually simultaneously, rather than inefficacy [2].…”

Section: Discussionmentioning

confidence: 99%

Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients

Mercadante

Ferrera

Villari

2006

Support Care Cancer

View full text Add to dashboard Cite

In six patients, dose increments of TD-BUP were effective, and patients achieved adequate analgesia within 6 days. Four patients discontinued the treatment due to inefficacy of TD-BUP 140 microg/h and were switched to other opioids until achieving stabilization (oxycodone 320 and 400 mg/day, methadone 120 mg/day, transdermal fentanyl 200 microg/h). This group of patients required higher doses than those chosen for TD-BUP, underlying the need to escalate the dose rapidly, a modality not accomplished with transdermal drugs. Adverse effects did not change and were similar to those observed before increasing the dose of TD-BUP. On the basis of these preliminary data, patients requiring doses higher than 70 microg/h of TD-BUP, in the range of 105-140 microg/h, may still have an analgesic benefit without important consequences in terms of adverse effects. It cannot be excluded that even higher doses may be effective, as some patients required rapid titration with higher morphine equivalent doses, and according to the protocol, other opioids were provided to facilitate this process. Further studies should clarify the role and the benefit of TD-BUP in specific clinical circumstances.

show abstract

Section: Discussionmentioning

confidence: 99%

Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients

Mercadante

Ferrera

Villari

2006

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…In a similar manner, two earlier publications describe the open-label use of the parenteral formulation of buprenorphine administered sublingually to treat patients with chronic pain (Adriaensen, Mattelaer, & Vanmeenen, 1985; Nasar, McLeavy, & Knox, 1986). Although most patients were followed up for less than one month, both studies reported good analgesia and low incidence or time-limited unwanted side effects.…”

Section: A Possible Role On the Use Of Buprenorphine For The Treatmenmentioning

confidence: 97%

Opioids and the treatment of chronic pain: Controversies, current status, and future directions.

Rosenblum

Marsch

Joseph

et al. 2008

Experimental and Clinical Psychopharmacology

577

383

View full text Add to dashboard Cite

Opioids have been regarded for millennia as among the most effective drugs for the treatment of pain. Their use in the management of acute severe pain and chronic pain related to advanced medical illness is considered the standard of care in most of the world. In contrast, the long-term administration of an opioid for the treatment of chronic non-cancer pain continues to be controversial. Concerns related to effectiveness, safety, and abuse liability have evolved over decades, sometimes driving a more restrictive perspective and sometimes leading to a greater willingness to endorse this treatment. The past several decades in the United States have been characterized by attitudes that have shifted repeatedly in response to clinical and epidemiological observations, and events in the legal and regulatory communities. The interface between the legitimate medical use of opioids to provide analgesia and the phenomena associated with abuse and addiction continues to challenge the clinical community, leading to uncertainty about the appropriate role of these drugs in the treatment of pain. This narrative review briefly describes the neurobiology of opioids and then focuses on the complex issues at this interface between analgesia and abuse, including terminology, clinical challenges, and the potential for new agents, such as buprenorphine, to influence practice.

show abstract

“…Studies using low‐dose sublingual buprenorphine showed improvements in analgesic outcome with starting doses as low as 0.1 mg in adults [24] and up to 3.2 mg/day where reported [25]. In the only randomized controlled trial identified, the authors demonstrated equivalence between sublingual buprenorphine 0.2–0.4 mg q.6–8h.…”

Section: Resultsmentioning

confidence: 97%

“…After screening of titles, abstracts, and full-text articles where applicable, only 10 studies met the inclusion criteria [18][19][20][21][22][23][24][25][26][27]. These trials were published between 1979 and 2012 and involved 1,190 patients originating from the United States [18,19,21,22] and Europe [20,[23][24][25][26][27]. Patient numbers in the studies ranged from five [21] to 453 [23].…”

Section: Description Of Included Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Sublingual Buprenorphine as an Analgesic in Chronic Pain: A Systematic Review

Cote

Montgomery

2014

Pain Med

View full text Add to dashboard Cite

show abstract

A long-term open assessment of sublingual buprenorphine in patients suffering from chronic pain

Cited by 10 publications

References 0 publications

Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients

Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients

Opioids and the treatment of chronic pain: Controversies, current status, and future directions.

Sublingual Buprenorphine as an Analgesic in Chronic Pain: A Systematic Review

Contact Info

Product

Resources

About